FDA clears Auron’s AUTX-703 IND to treat haematological malignancies

The proceeds are set to be utilised for progressing the therapy through a Phase I clinical proof-of-concept trial for AML. Credit: Prasesh Shiwakoti (Lomash) on Unsplash.